NEW YORK--(BUSINESS WIRE)-- The Law Offices of Vincent Wong notifies investors of an investigation concerning whether Meridian Bioscience, Inc. (“Meridian Bioscience”) (NASDAQ:VIVO) violated federal securities laws.
Click here to learn about the case: http://docs.wongesq.com/VIVO-Info-Request-Form-1610. There is no cost or obligation to you.
The investigation concerns Meridian’s subsidiary, Magellan Diagnostics Inc. On May 17, 2017, the U.S. Food and Drug Administration issued a field safety notice advising that customers discontinue use of Magellan’s lead testing system with venous blood samples, following a product recall. Then on October 23, 2017, Magellan received a warning letter from the FDA following an inspection. In its press release of the same day, the FDA stated that the warning letter was the result of “several violations of federal law” by Magellan, including “marketing significantly modified versions of two of its blood lead testing systems without the FDA’s required clearance or approval and failing to submit medical device reports to the FDA after becoming aware of customer complaints involving discrepancies in blood lead test results.”
To learn more about the investigation of Meridian contact Vincent Wong, Esq. either via email email@example.com, by telephone at 212.425.1140, or visit http://docs.wongesq.com/VIVO-Info-Request-Form-1610.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171107006695/en/
The Law Offices of Vincent Wong
Vincent Wong, Esq., 212-425-1140
Source: The Law Offices of Vincent Wong